Ultimovacs ASA Gains Prospectus Approval
Ultimovacs ASA is making headlines with its recent developments aimed at enhancing its business landscape. The Company, known for its pioneering work in immunotherapies, has taken another significant step forward by obtaining approval for its prospectus, an important document that outlines details about its upcoming share listing.
Collaboration for Enhanced Growth
On February 28, 2025, Ultimovacs ASA announced an ambitious Business Combination with Zelluna Immunotherapy AS. This merger is strategically designed to bolster their capabilities and expand their market offerings. The agreement is expected to lead to synergies that will provide greater value to both companies and their stakeholders.
Private Placement Shares and Business Combination
As part of this Business Combination, Ultimovacs is set to issue 147,991,521 Consideration Shares and 19,873,071 Private Placement Shares. Each of these shares carries a nominal value of NOK 0.10. This share issuance is pivotal for the merger as it lays the foundation for the Company's expansion efforts post-M&A activities.
Public Disclosure and Trading Information
In conjunction with the Business Combination, the Company’s prospectus has received the green light from Norway's Financial Supervisory Authority. Following this approval, the prospectus will be accessible to the public, allowing potential investors and interested parties to familiarize themselves with the forthcoming trading conditions of the Consideration Shares and Private Placement Shares.
Date of Trading Launch
The anticipated first day of trading for these shares is projected to be around March 4, 2025. Though contingent upon the successful conclusion of their Business Combination, this date generates excitement for investors looking to be part of Ultimovacs' growth trajectory.
Looking Ahead: A Promising Future
With the prospectus approval, Ultimovacs ASA is positioning itself for a segment of growth that could significantly influence its market presence. Investors are encouraged to monitor developments closely as the listing date approaches. The Company remains committed to providing transparency and updates throughout this crucial period.
Contacting Ultimovacs for Inquiries
For those seeking additional information, Ultimovacs encourages interested parties to reach out directly. Investors can contact Hans Vassgård Eid, CFO and Interim CEO, via email at hans.eid@ultimovacs.com or by phone at +47 482 48632.
Frequently Asked Questions
What is the significance of Ultimovacs' prospectus approval?
Approval of the prospectus marks a crucial milestone for Ultimovacs as it prepares for new share listings essential for growth following its business combination.
When will the trading for new shares begin?
Trading for the shares is expected to start on or about March 4, 2025, dependent on the successful completion of the Business Combination.
How many shares will Ultimovacs issue during the combination?
Ultimovacs plans to issue a total of 167,864,592 shares, consisting of both Consideration and Private Placement Shares.
Who can I contact for more information about Ultimovacs?
You can reach out to Hans Vassgård Eid by email at hans.eid@ultimovacs.com or by phone at +47 482 48632 for further inquiries.
What is Ultimovacs known for?
Ultimovacs ASA specializes in developing innovative immunotherapies aimed at treating cancer, contributing significantly to advancements in this critical field.
